The Time is NOW: Incorporating T1D Screening and Treatment Options into DSMES | Recording-The Time is NOW: Incorporating T1D Screening and Treatment Options into DSMES

Video Transcription

Video Summary

This webinar, “The Time Is Now: Type 1 Diabetes Screening and Treatment in DSMES,” reviews how healthcare professionals can identify and act on early-stage type 1 diabetes (T1D) and integrate screening into Diabetes Self-Management Education and Support (DSMES).<br /><br />Presenters outline T1D staging: Stage 1 (two or more islet autoantibodies with normal glucose), Stage 2 (autoantibodies plus dysglycemia), Stage 3 (symptomatic, meeting ADA diagnostic criteria), and Stage 4 (longstanding T1D). Screening is emphasized to reduce diabetic ketoacidosis (DKA) at diagnosis (reported up to 62%), avoid misdiagnosis (especially in adults), enable early education and planning, connect patients to research, and identify eligibility for interventions that delay progression—particularly teplizumab, an FDA-approved immune-modulating infusion for Stage 2 T1D in individuals age 8+.<br /><br />Recommended screening groups include first-degree relatives of people with T1D, individuals with personal/family autoimmune disease history, and those with questionable diabetes classification. General population screening is discussed because most new T1D cases lack a first-degree relative. Guidance is shared on rescreening intervals and monitoring; notable new ADA 2026 guidance highlights single confirmed IA-2 antibody as higher-risk, warranting monitoring similar to multiple antibodies.<br /><br />A DSMES-focused segment maps where to operationalize screening across standards: stakeholder engagement, service assessment, team training, curriculum integration (pathophysiology, monitoring, medications, risk reduction, coping), referral/assessment questions, goal-setting, outcomes tracking, and quality improvement projects.<br /><br />Panelists discuss real-world implementation, adult-system barriers, collaboration with educators, use of CGM samples, mental health referrals, and strategies to educate primary care and emergency departments to identify patients earlier.

Keywords

Type 1 diabetes screening

DSMES integration

T1D staging

Islet autoantibodies

Stage 1 T1D

Stage 2 T1D

Stage 3 T1D diagnosis

Diabetic ketoacidosis prevention

Teplizumab

Immune-modulating therapy

First-degree relative screening

General population screening

ADA 2026 guidance

IA-2 antibody risk

Diabetes misdiagnosis in adults